PAI
APRE icon

Palo Alto Investors’s Aprea Therapeutics APRE Stock Holding History

Palo Alto Investors’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,439
Closed -$634K – 43
2020
Q4 		$634K Buy
6,439
+449
+7% +$214K 0.03% 36
2020
Q3 		$2.88M Buy
5,990
+3,628
+154% +$2.03M 0.16% 29
2020
Q2 		$1.83M Buy
+2,362
New +$1.55M 0.11% 30

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Palo Alto Investors's APRE Position: Q1 2021 in Review

Palo Alto Investors sold out of Aprea Therapeutics (APRE) in Q1 2021, closing a stake of 6,439 shares — an estimated $634K sold.

Palo Alto Investors first reported a position in APRE in Q2 2020 and held it in 3 quarters. The position peaked at $2.88M in Q3 2020. 67 funds tracked by Wall St. Rank hold APRE as of Q1 2021.

  • Palo Alto Investors reported no remaining Aprea Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Palo Alto Investors sold 6,439 Aprea Therapeutics shares in Q1 2021, an estimated $634K.
  • Palo Alto Investors first reported a position in Aprea Therapeutics in Q2 2020 and held it in 3 quarters.
  • Palo Alto Investors's Aprea Therapeutics position peaked at $2.88M in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2021.

Based on Palo Alto Investors's 13F filing for Q1 2021, filed 17 May 2021.